Occurrence, resistance patterns, and management of carbapenemase-producing bacteria in war-wounded refugees from Ukraine

Int J Infect Dis. 2023 Jul:132:89-92. doi: 10.1016/j.ijid.2023.04.394. Epub 2023 Apr 16.

Abstract

We analyzed consecutive clinical cases of infections due to carbapenemase-producing gram-negative bacteria detected in war-wounded patients from Ukraine who were treated at one university medical center in southwest Germany between June and December 2022. The isolates of multiresistant gram-negative bacteria were subjected to a thorough microbiological characterization and whole genome sequencing (WGS). We identified five war-wounded Ukrainian patients who developed infections with New Delhi metallo-β-lactamase 1-positive Klebsiella pneumoniae. Two isolates also carried OXA-48 carbapenemases. The bacteria were resistant to novel antibiotics, such as ceftazidime/avibactam and cefiderocol. The used treatment strategies included combinations of ceftazidime/avibactam + aztreonam, colistin, or tigecycline. WGS suggested transmission during primary care in Ukraine. We conclude that there is an urgent need for thorough surveillance of multiresistant pathogens in patients from war zones.

Keywords: Antimicrobial resistance; Carbapenemase; Cefiderocol; Ceftazidime/avibactam; Klebsiella pneumoniae; Pseudomonas aeruginosa.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds / therapeutic use
  • Bacterial Proteins / genetics
  • Ceftazidime* / therapeutic use
  • Drug Combinations
  • Gram-Negative Bacteria / genetics
  • Humans
  • Klebsiella pneumoniae / genetics
  • Microbial Sensitivity Tests
  • Refugees*
  • Ukraine / epidemiology
  • beta-Lactamases / genetics

Substances

  • Ceftazidime
  • carbapenemase
  • avibactam
  • Anti-Bacterial Agents
  • beta-Lactamases
  • Bacterial Proteins
  • Azabicyclo Compounds
  • Drug Combinations